Miltenyi Biotec’s Post

More and more Cell and Gene Therapy (CGT) projects are entering biotech pipelines, leading to a subsequent rise in trial numbers. How can pharmaceutical companies effectively overcome the major delivery challenges of cell therapy products at the Point of Care (PoC) while considering the most accessible and cost-effective strategy? Read the recent article by Frank Altznauer Luisa Sterkel and Joana B. Loureiro here https://lnkd.in/enaCePFy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Beam Therapeutics CEO on CRISPR's future, sickle cell research: The Endpoints Slack interview: Even with last year’s landmark approvals for genetic medicines in sickle cell disease, John Evans is convinced his startup can push the field further. Beam Therapeutics started 2024 by announcing it had dosed the first sickle cell patient with its base-editing program, expecting initial human results in the second half of 2024. Endpoints News invited Evans, a former Agios Pharmaceuticals executive who has run Beam since 2017, to our secret Slack channel to talk about Beam’s sickle cell plans amid increasing competition, as well as how CRISPR could evolve over the next two decades. This conversation has been minimally edited for readability. Andrew Dunn John, welcome to the Endpoints Slack room! John Evans Hello! Great to be here Andrew Dunn how’s it feel to be our first guest of 2024? John Evans It’s a privilege! 2024 is going to be a lot better than 2023 in biotech — you heard it here first. Andrew Dunn that’s what I heard all week at JPM! well a lot to get into, i’m excited to maybe even sneak in some poetry questions later, we’ll see John Evans Ha — you got it. I’ll brush up on my Chaucer during the down times Andrew Dunn Excellent… But to start with some big news for this year in Beam’s first clinical readout in sickle cell, expected in the second half of the year Given the recent approvals — Vertex/CRISPR and bluebird — what’s the bar for success for Beam? Has it gone up over the past year, in terms of what you want to see for this initial readout and more broadly for the competitiveness of this program? John Evans No, it’s the same bar — our base case was always approval for Bluebird and approval for CRSP/VRTX. They are clearly good drugs and big improvements for patients. The benefit of BEAM-101 has always been to take that foundation and go even further, now using base editing for a more precise and efficient genetic correction, in a non-cutting, non-viral format. That’s exactly where we stand now with 101 in the clinic. So we’d like to show clinical data that demonstrates the potential superiority in the editing product, including more cells edited, higher levels of upregulation of F, and a more uniform outcomes across all cells. Our manufacturing process is also really strong and has been a subject of a lot of work by the team over the years. Andrew Dunn For this first readout later this year, will… #lucidquest #genetherapy #celltherapy

More and more cell therapies are making the exciting move from the lab to commercial manufacturing. This article discusses the challenges and strategies for a successful transition.

Bristol Myers Squibb Increases Investment in Cellares for Advancing Cell Therapy Manufacturing Bristol Myers Squibb (BMS) is expanding its partnership with cell and gene therapy manufacturer Cellares, utilizing Cellares' Cell Shuttle platform for automated proof-of-concept manufacturing of a second CAR-T cell therapy. The financial details of the agreement remain undisclosed, but it deepens the collaboration between the two companies. Cellares, known for its innovative automation platform, recently raised $255 million in funding, with BMS as a key contributor. BMS, a major player in cell therapy, continues to strengthen its position in the field. If you want to stay informed about the latest developments in the pharmaceutical industry, visit Pharmtales. They provide up-to-date coverage of the Latest Pharma News. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #bristolmyerssquibb #celltherapy #celltherapymanufacturing #cellarescorporation https://lnkd.in/dkWy6CAe

Gene&Cell Therapy >> Beam Therapeutics CEO on CRISPR's future, sickle cell research: The Endpoints Slack interview: Even with last year’s landmark approvals for genetic medicines in sickle cell disease, John Evans is convinced his startup can push the field further. Beam Therapeutics started 2024 by announcing it had dosed the first sickle cell patient with its base-editing program, expecting initial human results in the second half of 2024. Endpoints News invited Evans, a former Agios Pharmaceuticals executive who has run Beam since 2017, to our secret Slack channel to talk about Beam’s sickle cell plans amid increasing competition, as well as how CRISPR could evolve over the next two decades. This conversation has been minimally edited for readability. Andrew Dunn John, welcome to the Endpoints Slack room! John Evans Hello! Great to be here Andrew Dunn how’s it feel to be our first guest of 2024? John Evans It’s a privilege! 2024 is going to be a lot better than 2023 in biotech — you heard it here first. Andrew Dunn that’s what I heard all week at JPM! well a lot to get into, i’m excited to maybe even sneak in some poetry questions later, we’ll see John Evans Ha — you got it. I’ll brush up on my Chaucer during the down times Andrew Dunn Excellent… But to start with some big news for this year in Beam’s first clinical readout in sickle cell, expected in the second half of the year Given the recent approvals — Vertex/CRISPR and bluebird — what’s the bar for success for Beam? Has it gone up over the past year, in terms of what you want to see for this initial readout and more broadly for the competitiveness of this program? John Evans No, it’s the same bar — our base case was always approval for Bluebird and approval for CRSP/VRTX. They are clearly good drugs and big improvements for patients. The benefit of BEAM-101 has always been to take that foundation and go even further, now using base editing for a more precise and efficient genetic correction, in a non-cutting, non-viral format. That’s exactly where we stand now with 101 in the clinic. So we’d like to show clinical data that demonstrates the potential superiority in the editing product, including more cells edited, higher levels of upregulation of F, and a more uniform outcomes across all cells. Our manufacturing process is also really strong and has been a subject of a lot of work by the team over the years. Andrew Dunn For this first readout later this year, will you have clinical data on that criteria? Like… #lucidquest #genetherapy #celltherapy

How to increase manufacturing capacity with increasing number of approvals of innovative cell and gene therapies #genetherapy #celltherapy

Kevin Friedman, chief executive officer and founder of Kelonia, said that the collaboration holds “revolutionary promise” and that “combining Kelonia’s in vivo gene delivery capabilities with the ACCEL convertible CAR technology is an ideal marriage of technologies to create off-the-shelf, universal CAR-T cell therapies”. #DahliaConsulting #BiopharmaceuticalIndustry #CommercialLifeSciences #ManagementConsultant #LifeSciencesBusinessStrategy #GlobalPharma #GlobalBioTech #SupplychainOperations #CommercialOperations #CGTcommercialization #Manufacturing #QualityAssurance #OperationalExcellence #FinancialAnalysis #OpModelDesign #LifeScience #BioTechnology #Bioprocessing #Biosimilars #BioPharmaIndustry #MedicalResearch #CDMO #GMP #GMPbatch #GMPmanufacturing #GenomeEditing #GeneTherapy #CellTherapy #Car_T #mRNA #cGMP #ClinicalGradeManufacturing #ClinicalGradeProduction #BiologicsLicenseApplication #BLA #Pharmaceuticals #RegenerativeMedicine #Astellas #XyphosBiosciences #ACCELTechnology #PMLive